Metabolism and pharmacokinetics of EAPB0203 and EAPB0503, two imidazoquinoxaline compounds previously shown to have antitumoral activity on melanoma and T-lymphomas

Drug Metabolism and Disposition

Volumn 38, Issue 10, 2010, Pages 1836-1847

  Khier, Sonia ^a   Gattacceca, Florence ^a   El Messaoudi, Safia ^a   Lafaille, Florian ^a   Deleuze Masquéfa, Carine ^a   Bompart, Jacques ^a   Cooper, Jean François ^b   Solassol, Isabelle ^c   Pinguet, Frédéric ^c   Bonnet, Pierre Antoine ^a   Bressolle, Françoise M M ^a  

^a UNIV MONTPELLIER   (France)

^b UNIVERSITÉ DE PERPIGNAN   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 PHENETHYL)IMIDAZO[1,2 A]QUINOXALIN 4 AMINE; 1 (3 HYDROXYPHENYL) N METHYLIMIDAZO[1,2 A]QUINOXALIN 4 AMINE; 1 (3 HYDROXYPHENYL)IMIDAZO[1,2 A]QUINOXALIN 4 AMINE; 1 (3 METHOXYPHENYL) N METHYLIMIDAZO[1,2 A]QUINOXALIN 4 AMINE; 1 (3 METHOXYPHENYL)IMIDAZO[1,2 A]QUINOXALIN 4 AMINE; ANTINEOPLASTIC AGENT; EAPB 0202; EAPB 0203; EAPB 0502; EAPB 0503; EAPB 0602; EAPB 0603; KETOCONAZOLE; N METHYL 1 (2 PHENETHYL)IMIDAZO[1,2 A]QUINOXALIN 4 AMINE; QUINOXALINE DERIVATIVE; SERUM ALBUMIN; SULFAPHENAZOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOTOXICITY; DEMETHYLATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG TRANSFORMATION; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; HYDROXYLATION; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; T CELL LYMPHOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; BLOOD PROTEINS; DOGS; HUMANS; LYMPHOMA, T-CELL; MELANOMA; MICE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; PROTEIN BINDING; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TISSUE DISTRIBUTION;

CANIS FAMILIARIS; MAMMALIA; RATTUS;

EID: 77957102897     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.034579     Document Type: Article

References (38)

1. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
2. Bourrié M, Meunier V, Berger Y, and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332. (Pubitemid 27169077)
3. Carlile DJ, Zomorodi K, and Houston JB (1997) Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. Drug Metab Dispos 25:903-911. (Pubitemid 27357686)
4. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
5. Deleuze-Masquéfa C, Gerebtzoff G, Subra G, Fabreguettes JR, Ovens A, Carraz M, Strub MP, Bompart J, George P, and Bonnet PA (2004) Design and synthesis of novel imidazo[1,2-a]quinoxalines as PDE4 inhibitors. Bioorg Med Chem 12:1129-1139. (Pubitemid 38251304)
6. Deleuze-Masquéfa C, Moarbess G, Bonnet PA, Pinguet F, Bazarbachi A, and Bressolle F (2009), inventors; University of Montpellier I, American University of Beirut, Centre Régional de Lutte Contre le Cancer de Montpellier, assignees. Imidazo[1,2-a]quinoxalines and derivatives thereof for treating cancers. World patent WO/2009/043934. 2009 April 9.
7. Deleuze-Masquéfa C, Moarbess G, Khier S, David N, Gayraud-Paniagua S, Bressolle F, Pinguet F, and Bonnet PA (2009) New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma. Eur J Med Chem 44:3406-3411.
8. Eagling VA, Tjia JF, and Back DJ (1998) Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45:107-114.
9. Ermondi G, Lorenti M, and Caron G (2004) Contribution of ionization and lipophilicity to drug binding to albumin: a preliminary step toward biodistribution prediction. J Med Chem 47:3949-3961. (Pubitemid 38970957)
10. Farenc C, Fabreguette JR, and Bressolle F (2000) Pk-fit: a pharmacokinetic/pharmacodynamic and statistical data analysis software. Comput Biomed Res 33:315-329.
11. Halpert JR, Guengerich FP, Bend JR, and Correia MA (1994) Selective inhibitors of cytochromes P450. Toxicol Appl Pharmacol 125:163-175.
12. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
13. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, et al. (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662-670.
14. Hengge UR and Cusini M (2003) Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. Br J Dermatol 149:15-19.
15. Jia L and Liu X (2007) The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr Drug Metab 8:822-829. (Pubitemid 350238912)
16. Kang HY, Park TJ, and Jin SH (2009) Imiquimod, a Toll-like receptor 7 agonist, inhibits melanogenesis and proliferation of human melanocytes. J Invest Dermatol 129:243-246.
17. Khier S, Deleuze-Masquéfa C, Moarbess G, Gattacceca F, Margout D, Solassol I, Cooper JF, Pinguet F, Bonnet PA, and Bressolle FM (2010) Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma. Eur J Pharm Sci 39:23-29.
18. Khier S, Moarbess G, Deleuze-Masquéfa C, Solassol I, Margout D, Pinguet F, Bonnet PA, and Bressolle FM (2009) Quantitation of imidazo[1,2-a]quinoxaline derivatives in human and rat plasma using LC/ESI-MS. J Sep Sci 32:1363-1373.
19. Lin JJ, Meyer JD, Carpenter JF, and Manning MC (2000) Stability of human serum albumin during bioprocessing: denaturation and aggregation during processing of albumin paste. Pharm Res 17: 391-396.
20. Moarbess G, Deleuze-Masquéfa C, Bonnard V, Gayraud-Paniagua S, Vidal JR, Bressolle F, Pinguet F, and Bonnet PA (2008a) In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives. Bioorg Med Chem 16:6601-6610. (Pubitemid 351802212)
21. Moarbess G, El-Hajj H, Kfoury Y, El-Sabban ME, Lepelletier Y, Hermine O, Deleuze-Masquéfa C, Bonnet PA, and Bazarbachi A (2008b) EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma. Blood 111:3770-3777.
22. Morjaria S, Deleuze-Masquéfa C, Lafont V, Gayraud S, Bompart J, Bonnet PA, and Dornand J (2006) Impairment of TNF-α production and action by imidazo[1,2-α]quinoxalines, a derivative family which displays potential anti-inflammatory properties. Int J Immunopathol Pharmacol 19:525-538. (Pubitemid 44580525)
23. Naritomi Y, Terashita S, Kagayama A, and Sugiyama Y (2003) Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 31:580-588. (Pubitemid 36444167)
24. Nassar AF, Hollenberg PF, and Scatina JA (2009) Drug Metabolism Handbook: Concepts and Applications (Hoboken NJW ed) pp 149-150, John Wiley & Sons Ltd., Chichester, UK.
25. Newton DJ, Wang RW, and Lu AY (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
26. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
27. Pearce R, Greenway D, and Parkinson A (1992) Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch Biochem Biophys 298:211-225.
28. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, and Harris JW (1994) Selective biotransformation of taxol to 6-α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546.
29. Reidy GF, Mehta I, and Murray M (1989) Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Mol Pharmacol 35:736-743. (Pubitemid 19138926)
30. Rendic S and Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-580. (Pubitemid 27293618)
31. Rodrigues AD (1994) Use of in vitro human metabolism studies in drug development. An industrial perspective. Biochem Pharmacol 48:2147-2156. (Pubitemid 24374702)
32. Rudy SJ (2002) Imiquimod (Aldara): modifying the immune response. Dermatol Nurs 14:268-270.
33. Sauder DN (2003) Imiquimod: modes of action. Br J Dermatol 149:5-8.
34. Scatchard G (1949) The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51:660-672.
35. Spaner DE, Miller RL, Mena J, Grossman L, Sorrenti V, and Shi Y (2005) Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leuk Lymphoma 46:935-939. (Pubitemid 40959685)
36. Steinmann A, Funk JO, Schuler G, and von den Driesch P (2000) Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 43:555-556. (Pubitemid 30666755)
37. van Egmond S, Hoedemaker C, and Sinclair R (2007) Successful treatment of perianal Bowen's disease with imiquimod. Int J Dermatol 46:318-319. (Pubitemid 46390296)
38. Yang J, Jamei M, Yeo KR, Rostami-Hodjegan A, and Tucker GT (2007) Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos 35:501-502.